Cantor Fitzgerald has increased its price target for Eli Lilly's stock following the company's recent guidance. This adjustment reflects the firm's confidence in Eli Lilly's financial outlook and performance projections. The new target is expected to influence investor sentiment and trading activity related to the pharmaceutical company's shares. Eli Lilly continues to be a significant player in the healthcare sector, with ongoing developments in its product pipeline.
Related Articles
Don't miss out on breaking stories and in-depth articles.